The following groups of comparisons were formed: (1) BCR versus BRF cases within the TMPRSS2–ERG molecular subtype and (2) BCR versus BRF cases within the TMPRSS2–ERG molecular subtype in the TCGA–PRAD cohort. This evidence concerns the gene ERG and prostate adenocarcinoma.